马林克罗德的THERAKOSTM CELLEXTM光电系统获得了欧盟MDR 2017/745认证. Mallinckrodt's THERAKOS™ CELLEX™ Photopheresis System receives EU MDR 2017/745 certification.

Mallinckrodt plc宣布,其THERRAKOSTM CELLEXTM光谱截图系统已经根据欧盟2017/745年医疗设备条例(EU MDR)获得CE认证。 Mallinckrodt plc announced that its THERAKOS™ CELLEX™ Photopheresis System has received CE Certification under the EU Medical Device Regulation (EU MDR) 2017/745. 这种认证确保安全并支持医疗设备的创新。 This certification ensures safety and supports innovation for medical devices. CELLEX系统是全球唯一完全一体化的外体外光谱系统,用于治疗Cutaneous T Cell Lymphoma、器官移植排斥和移植与宿主疾病。 The CELLEX system, the only fully integrated Extracorporeal Photopheresis system globally, is used for treating Cutaneous T Cell Lymphoma, organ transplant rejection, and graft versus host disease.